Sponsors
The bill improves federal coordination, oversight of emerging defense‑critical technologies, and planning for a biomanufacturing reserve—but does so by adding studies, meetings, and administrative layers that raise near‑term costs, risk delaying urgent action, and could create market‑distorting policy scope.
Federal agencies, defense planners, and technology experts will get more regular coordination and focused oversight because the Committee must meet at least twice yearly and a new Subcommittee on Emerging Technology will analyze AI, semiconductors, biotech, etc., improving identification of technologies critical to defense and supply-chain resilience.
U.S. manufacturers and supply‑chain actors could see targeted cross‑agency efforts to address supply‑chain gaps and innovation bottlenecks because the bill authorizes subcommittees to coordinate on those issues, potentially improving domestic production resilience and industrial efficiency.
Federal planners and taxpayers will receive a clear, government-led analysis of the benefits, costs, and required resources for creating a U.S. biomanufacturing reserve because the bill mandates an evaluation to support DPA national defense needs.
Taxpayers and federal staff will face higher near‑term administrative costs and time burdens because the bill creates new meetings, subcommittees, and studies that require agency staff time and resources without delivering immediate operational capabilities.
Urgent biothreat or pandemic gaps may remain unaddressed in the near term because the bill prioritizes study and planning for a biomanufacturing reserve rather than immediate procurement or capacity fixes.
Taxpayers could face substantial long‑term costs if the evaluation leads to building and sustaining an expensive biomanufacturing reserve, increasing federal spending to construct and maintain capacity identified as necessary for defense.
Based on analysis of 4 sections of legislative text.
Creates a DPA Subcommittee on Emerging Technology, mandates twice‑yearly Committee meetings, and requires an 18‑month report on building a strategic biomanufacturing reserve.
Introduced March 24, 2026 by Stephen F. Lynch · Last progress March 24, 2026
Creates a standing Subcommittee on Emerging Technology within the Defense Production Act (DPA) Committee, requires the DPA Committee to meet at least twice per year, and empowers the Committee chair to create subcommittees for better interagency coordination. Directs the new Subcommittee on Emerging Technology to define “covered technology” (listing candidate areas such as AI, robotics, biotechnology, semiconductors, quantum, materials science, cryptography, and space) and to deliver to Congress within 18 months an evaluation of the benefits, drawbacks, and resource needs for establishing a strategic reserve of critical biomanufacturing capacity to meet national defense requirements under the DPA. Also makes a minor stylistic correction to the DPA short-title quotation. The bill itself does not appropriate funds or create immediate procurement authorities; it sets meeting requirements, creates a study and reporting requirement, and clarifies organizational authority for interagency coordination on emerging technologies.